Insulin lever to 11
GLP-1
+1

Jul 16, 2026
•
10 min read
A guest post by Jen Can NuSH on liver concerns and small molecule GLP1 medications
GLP-1
+3

Jul 2, 2026
•
14 min read
Orals, Triples, Biologics and even more data from ADA 2026
GLP-1
+4

Jul 1, 2026
•
5 min read
New phase 1b data shows incredible weight loss
GLP-1
+2

Jun 19, 2026
•
18 min read
A tale of dual agonists, glucagon or amylin, who wins the insulin sensitivity race?
GLP-1
+3

Jun 9, 2026
•
12 min read
A paradigm shift in diabetes and obesity arrives!
GLP-1
+6

May 29, 2026
•
10 min read
The Super Bowl Conference for diabetes and incretins!
GLP-1
+3
May 21, 2026
•
4 min read
Triumph 1 trial led to 19-30% weight loss depending on dose and time on trial.
GLP-1
+1

Apr 16, 2026
•
2 min read
Orforglipron reduces the risk of cardiovascular events and all cause death in diabetic patients
GLP-1
+3

Mar 19, 2026
•
7 min read
A shift in what's possible for diabetes and obesity
GLP-1
+2

Mar 11, 2026
•
11 min read
More early trial results from some new players in the obesity medicine space
GLP-1
+5

Dec 16, 2025
•
40 min read
Incretins are changing the narrative of chronic kidney disease
GLP-1
+3

Dec 11, 2025
•
10 min read
Bariatric surgery in a shot! It might be too effective?! And what's dysesthesia?
GLP-1
+2

Nov 14, 2025
•
31 min read
Orforglipron, HRS 9531, MET-097, Eloralintide and Mazdutide, OH MY!
GLP-1
+1

Sep 5, 2025
•
13 min read
Less nausea, more insulin sensitivity, and a little less inflammation Part 2 in a series on GIP
GLP-1
+2

Jul 29, 2025
•
15 min read
The master incretin of the alpha and beta cell starts to shinePart 1 in a series on GIP

A collection of collated data on incretin drug developments, including new drugs, new treatments and the future of incretin in medicine